AVALO THERAPEUTICS, INC.

(AVTX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Avalo Therapeutics Appoints Chief Commercial Officer

01/11/2022 | 03:54am EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
AVALO THERAPEUTICS, INC. -0.22% 0.3193 Delayed Quote.-81.22%
SWEDISH ORPHAN BIOVITRUM AB (PUBL) -1.03% 210.4 Delayed Quote.13.67%
All news about AVALO THERAPEUTICS, INC.
05/24AVALO THERAPEUTICS : Announces First Patient Dosed in the Phase 2 PEAK Trial of AVTX-002 f..
PU
05/24AVALO THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
05/23Mind Medicine Names Schond Greenway as CFO
MT
05/18Avalo Therapeutics Doses First Patient in Phase 2 Trial of Asthma Treatment Candidate
MT
05/18Avalo Therapeutics Announces First Patient Dosed in the Phase 2 PEAK Trial of AVTX-002 ..
GL
05/18Avalo Therapeutics, Inc. Announces First Patient Dosed in the Phase 2 PEAK Trial of AVT..
CI
05/17Avalo to Present at the H.C. Wainwright Global Life Sciences Conference
GL
05/06RBC Halves Price Target on Avalo Therapeutics to $2 From $4, Noting 'Early Stage Risk W..
MT
05/05AVALO THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition a..
AQ
05/05Avalo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31,..
CI
More news
Analyst Recommendations on AVALO THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2022 3,98 M - -
Net income 2022 -73,6 M - -
Net Debt 2022 - - -
P/E ratio 2022 -0,55x
Yield 2022 -
Capitalization 36,0 M 36,0 M -
Capi. / Sales 2022 9,05x
Capi. / Sales 2023 5,11x
Nbr of Employees 43
Free-Float 99,3%
Chart AVALO THERAPEUTICS, INC.
Duration : Period :
Avalo Therapeutics, Inc. Technical Analysis Chart | AVTX | US05338F1084 | MarketScreener
Technical analysis trends AVALO THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 0,32 $
Average target price 3,55 $
Spread / Average Target 1 012%
EPS Revisions
Managers and Directors
Garry Arthur Neil President & Chief Executive Officer
Christopher Sullivan Chief Financial Officer
Steven Joseph Boyd Chairman
Lisa Hegg Vice President-Research & Development Programs
Gunnar Magnus Modee Persson Lead Independent Director
Sector and Competitors
1st jan.Capi. (M$)
AVALO THERAPEUTICS, INC.-81.22%36
MODERNA, INC.-41.86%58 733
LONZA GROUP AG-24.79%44 437
IQVIA HOLDINGS INC.-21.85%41 736
SEAGEN INC.-8.54%26 026
ICON PUBLIC LIMITED COMPANY-26.61%18 478